A Personalized Gene Therapy Helped Two Boys With Severe Epilepsy
Two individualized antisense treatments reduced the effects of a rare SCN2A disorder. The results are hopeful, but they come from two carefully monitored patients, not a broad trial.
Aug 1, 2026












